
New treatment options to battle hormone-refractory prostate carcinoma (PC) are a pressing medical need. Chronic inflammation has been implicated in PC etiology. The pro-inflammatory cytokines IL-6, IL-23 and IL-17 are critical mediators in promoting PC growth. Here, the study evaluates the potential of immunoproteasome inhibition for PC's anti-inflammatory and direct anti-tumorigenic therapy. Thus, immunoproteasome inhibition shows remarkable efficacy against PC progression in vivo and impedes tumor recurrence in CRPC-TRAMP mice by blocking the immunosuppressive inflammatory response in the tumor microenvironment. In conclusion, it shows that the immunoproteasome is a promising drug target for the treatment of PC.
Like
Save
Share